Real-world outcomes of autologous and allogeneic hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma in the era of novel therapies: a Canadian perspective

•Both autologous and allogeneic hematopoietic cell transplant have a curative potential•Novel therapies such as BV or CPIs are not curative, and duration of response is limited•Allogeneic hematopoietic cell transplant should be strongly considered for patients who relapse following autologous transplant•At time of HL relapse, early referral to a transplant center is mandatory